The objective of this “real life” study was to evaluate the effect of omalizumab treatment of allergic asthma by CD‐sens, as an objective marker of responders/non‐responders regarding the IgE‐mediated inflammation, and to relate the outcome to SPT and clinical parameters like FEV1, FEV1/FVC, Fractional exhaled Nitric Oxide (FeNO), Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE). This evidence concerns the gene IGHE and asthma.